Baricitinib helps regrow hair in teens with severe alopecia areata.
1 citations
,
January 2024 in “Arab Board Medical Journal” Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.
Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.
March 2023 in “PARIPEX INDIAN JOURNAL OF RESEARCH” Tofacitinib helped regrow hair in most patients with severe hair loss.
January 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in severe alopecia areata patients.
14 citations
,
July 2012 in “Journal of the American Academy of Dermatology” Topical tacalcitol ointment can help improve symptoms of EFFC.
A lotion with tretinoin, minoxidil, and betamethasone valerate helped treat a woman's skin infection.
January 2016 in “Huanjing yu Jiankang Zazhi”
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
51 citations
,
June 2016 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
The supplement improved hair density and overall hair beauty.
January 2016 in “Jurnal Farmasi Indonesia” The 10% hibiscus leaf extract hair tonic promotes better hair growth than 2% minoxidil but causes eye irritation.
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.
October 2025 in “International Journal of Risk & Safety in Medicine” Oral tofacitinib successfully treated a girl's severe skin and hair conditions.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
June 2025 in “Healthy-Mu Journal” The optimized Cinchonine gel effectively fights acne bacteria and is safe for twice-daily use.
February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
October 2008 in “Clin-alert” Certain medications can reduce mortality risk in COPD patients, but others can increase risks of cardiovascular issues, postoperative delirium, and other adverse effects.
6 citations
,
March 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective for long-term treatment of severe alopecia areata.
5 citations
,
August 2018 in “PubMed” An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.
March 2026 in “Indian Journal of Dermatology” Baricitinib can cause excessive hair growth.
January 2025 in “Biomedical Reports” Telitacicept helped stabilize complement levels in a patient with lupus and thyroid cancer.
12 citations
,
June 2010 in “Journal of dermatology” Some patients with severe alopecia areata developed skin darkening from their treatment, which may indicate a less effective response to the therapy.
7 citations
,
January 2016 in “Hair therapy & transplantation” People with early graying hair often have lower levels of iron, ferritin, and calcium.
September 2024 in “JAMA Dermatology” Low-dose metformin may help hair regrowth and reduce inflammation in CCCA.
46 citations
,
January 2008 in “Journal of cosmetic dermatology” Caffeine and siloxanetriol alginate caffeine in emulsion form can reduce fatty cell size and number, potentially treating cellulite effectively.
28 citations
,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
7 citations
,
August 2024 in “Clinical and Experimental Dermatology” Upadacitinib is effective and safe for treating severe alopecia areata in teens.
97 citations
,
January 2020 in “Advances in chronic kidney disease” Calcineurin inhibitors, used in kidney transplants, can cause a wide range of side effects including kidney damage and other health issues.